- Home
- OSRH vs BLRX Comparison
OSRH vs BLRX Comparison
Compare OSRH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSRH
- BLRX
- Stock Information
- Founded
- OSRH N/A
- BLRX 2003
- Country
- OSRH United States
- BLRX Israel
- Employees
- OSRH N/A
- BLRX N/A
- Industry
- OSRH
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OSRH
- BLRX Health Care
- Exchange
- OSRH Nasdaq
- BLRX Nasdaq
- Market Cap
- OSRH 19.0M
- BLRX 17.0M
- IPO Year
- OSRH N/A
- BLRX 2011
- Fundamental
- Price
- OSRH $0.98
- BLRX $4.25
- Analyst Decision
- OSRH
- BLRX Strong Buy
- Analyst Count
- OSRH 0
- BLRX 2
- Target Price
- OSRH N/A
- BLRX $19.00
- AVG Volume (30 Days)
- OSRH 927.3K
- BLRX 36.3K
- Earning Date
- OSRH 08-24-2025
- BLRX 08-14-2025
- Dividend Yield
- OSRH N/A
- BLRX N/A
- EPS Growth
- OSRH N/A
- BLRX N/A
- EPS
- OSRH N/A
- BLRX N/A
- Revenue
- OSRH N/A
- BLRX $22,340,000.00
- Revenue This Year
- OSRH N/A
- BLRX N/A
- Revenue Next Year
- OSRH N/A
- BLRX N/A
- P/E Ratio
- OSRH N/A
- BLRX N/A
- Revenue Growth
- OSRH N/A
- BLRX 91.68
- 52 Week Low
- OSRH $0.90
- BLRX $2.30
- 52 Week High
- OSRH $13.40
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- OSRH N/A
- BLRX 43.97
- Support Level
- OSRH N/A
- BLRX $4.47
- Resistance Level
- OSRH N/A
- BLRX $4.75
- Average True Range (ATR)
- OSRH 0.00
- BLRX 0.30
- MACD
- OSRH 0.00
- BLRX -0.04
- Stochastic Oscillator
- OSRH 0.00
- BLRX 11.96
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.